GlassScriptPhysician profile
Juan Castillo
NPI 1295222008
$2,640.16
in general payments reported to CMS, 2019-2025
25 companies · $965 in 2025
The $965 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $612 · 2024: $1,062 · 2025: $965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,640.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,640.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $240.44 | 2024-2025 | Korlym |
| Organogenesis INC. | $219.26 | 2024-2025 | Puraply Wound Matrix, Apligraf, Affinity |
| Inspire Medical Systems, INC. | $202.76 | 2023-2025 | Inspire |
| Beta Bionics, INC. | $193.19 | 2024 | Ilet Bionic Pancreas |
| Medtronic, INC. | $169.62 | 2023-2025 | Minimed 780g |
| Novartis Pharmaceuticals Corporation | $138.77 | 2025 | |
| Radius Health, INC. | $137.93 | 2024-2025 | Tymlos |
| Advanced Oxygen Therapy INC. | $125.54 | 2023 | Topical Oxygen Chamber For Extremities |
| Ascendis Pharma Endocrinology INC | $125.01 | 2025 | Yorvipath |
| Horizon Therapeutics Plc | $125.00 | 2023 | Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $121.57 | 2024-2025 | |
| Paragon 28, INC. | $109.33 | 2025 | Portfolio |
| Tandem Diabetes Care, INC. | $86.43 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $85.55 | 2023-2025 | Freestyle Libre 3 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $83.37 | 2025 | Evkeeza |
| Solventum Corporation | $67.49 | 2024-2025 | Prevena, V.A.C. Veraflo |
| Amgen INC. | $65.20 | 2023-2024 | Prolia, Evenity |
| Xeris Pharmaceuticals, INC. | $63.81 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Dexcom, INC. | $47.09 | 2023-2025 | Dexcom G6 Transmitter |
| Stryker Corporation | $25.92 | 2025 | |
| Lilly USA, LLC | $22.63 | 2023 | Mounjaro |
| Hartmann USA, INC. | $21.11 | 2023 | Zetuvit Plus |
| Recordati_rare_diseases_inc. | $20.68 | 2024 | Signifor Lar, Isturisa |
| Integra Lifesciences Corporation | $17.46 | 2024 | Tcc-Ez |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Castillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.